Biophysics in Drug Discovery 2018
Developing the Synergy between Biophysics and Medicinal Chemistry to Deliver Better Drugs
Boston, USA June 13-15, 2018
Registration
Welcome Address
OC01 - Making Off-Rate Screening in FBDD More Amenable For Fast Dissociating Compounds
Dr Menachem GUNZBURG
MONASH UNIVERSITY, Parkville, Australia
OC02 - Novel Active Site and Allosteric Site Binders Identified for FPPS Of T. cruzi
Ms Joy PETRICK
NOVARTIS, Basel, Switzerland
OC03 - Dynamic Single-Molecule Approaches to Accelerate the Development of More Efficient Drugs
Dr Gerrit SITTERS
LUMICKS, Amsterdam, The Netherlands
OC04 - Quantitative Irreversible Tethering (QIT) for Covalent Ligand Discovery
Dr Gregory CRAVEN
IMPERIAL COLLEGE LONDON, London, United Kingdom
OC05 - Large Protein Conformational Changes in Pi3kgamma Linked to the Binding of a New Class of Highly Selective Inhibitors
Dr Göran DAHL
ASTRAZENECA, Mölndal, Sweden
IL01 - Binding Kinetics and Thermodynamics in Drug Discovery
Dr Chaohong SUN
ABBVIE, North Chicago, United States
Coffee Break
Session Chair
Dr Daniel WYSS
MERCK, Kenilworth, United States
IL02 - Chemical Probes for Epigenetic Targets
Prof. Masoud VEDADI
STRUCTURAL GENOMICS CONSORTIUM, Toronto, Canada
Exhibitor Short Presentation: Bruker
Development and Proof-of-Concept of a New Flow-through System for High Resolution NMR to Evaluate Biologics-producing Cell Lines and Their Growth Environments
Dr Jason S. WOOD
BRUKER BIOSPIN, Billerica, United States
Exhibitor Short Presentation: Creoptix
The Wave of the Future in Kinetics
Dr Matyas VEGH
CREOPTIX AG, Wädenswil, Switzerland
OC06 - Quantification of Target Occupancy in Cells and Tumor Tissue Using FCCS
Dr Frank BECKER
INTANA BIOSCIENCE GMBH, Planegg, Germany
IL03 - How to Be Selectively Promiscuous
Prof. Jack TAUNTON
UNIVERSITY OF CALIFORNIA, San Francisco, United States
Session Chair
Dr Daniel WYSS
MERCK, Kenilworth, United States
KL01 - From Simulations of Biomolecules to Fighting Diseases
Prof. Martin KARPLUS
UNIVERSITY OF STRASBOURG, FRANCE & HARVARD UNIVERSITY, Cambridge, United States
Welcome Reception
End of the Day
Registration
IL04 - How Low Can You Go? Size and Resolution Limits Using Conventional Cryo-EM
Dr Gabriel LANDER
THE SCRIPPS RESEARCH INSTITUTE, San Diego, United States
IL05 - Cryo-EM for Characterization and Structure Based Drug Design
Dr Bridget CARRAGHER
NEW YORK STRUCTURAL BIOLOGY CENTER, New York, United States
Coffee Break
OC07 - Cryo-EM to Address Intractable Targets in Drug Discovery
Dr Hervé REMIGY
THERMO FISHER SCIENTIFIC, Eindhoven, The Netherlands
OC08 - Strength of Cryo-EM in Drug Discovery: One Could Always See Something
Dr Wen-ti LIU
NOVALIX, Illkirch, France
IL06 - Single Particle Cryo-EM Structure of the Insulin Receptor:Insulin Complex
Dr Giovanna SCAPIN
MERCK & CO. INC (MSD), Whitehouse Station, United States
Poster Session
Lunch & Networking
Session Chair
Dr Dan ERLANSON
CARMOT THERAPEUTICS, South San Francisco, United States
IL07 - New Tools Reveal Mechanisms of Allosteric Coupling in Human GPCRs
Dr Matthew EDDY
UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, United States
Exhibitor Short Presentation: Pall ForteBio
Dissecting Biomolecular Interactions - Pall ForteBio’s Next Gen SPR and BLI Label-Free Platforms: Providing Faster and Easier Solutions to Your Emerging Applications
Mr Bob DASS
PALL FORTEBIO, Menlo Park, United States
OC09 - Enabling NMR-Based Fragment Screening Using Stabilized Native GPCR: Case Study of Adenosine Receptor
Dr Anass JAWHARI
CALIXAR, Lyon, France
OC10 - Crystal Structures of Human Glycine Receptor Alpha3 Bound to a Novel Class of Analgesic Potentiators
Dr Xin HUANG
AMGEN, Cambridge, United States
IL08 - Structural Insight into Allosteric Modulation of GPCRs
Dr Miles CONGREVE
HEPTARES, Welwyn Garden City, United Kingdom
Coffee Break
Session Chair
Dr MariJean EGGEN
ELI LILLY, Indianapolis, United States
IL09 - Design Considerations for Synthetic Macrocycles in Drug Discovery
Prof. Adrian WHITTY
BOSTON UNIVERSITY, Boston, United States
OC11 - Use of Complementary Biophysical Methods to Characterize Ligand Binding to IL-17A
Dr Parag SAHASRABUDHE
PFIZER, Groton, United States
OC12 - Systematic Development of Small Molecules to Inhibit Specific Microscopic Steps of α-Synuclein Aggregation in Parkinson’s Disease
Ms Roxine STAATS
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
IL10 - Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction
Dr Shilin XU
UNIVERSITY OF MICHIGAN, Michigan, United States
Posters & Drinks
End of the Day
Conference Dinner
Registration
Session Chair
Dr Jim BRYSON
BRISTOL-MYERS-SQUIBB, Princeton, United States
IL11 - Attacking the Cancer Cell Surface-ome with Recombinant Antibodies
Prof. Jim WELLS
UCSF, San Francisco, United States
Exhibitor Short Presentation: Sierra Sensors
Controlling Throughput for SPR
Dr Christopher WHALEN
SIERRA SENSORS, Greenville, United States
IL12 - Multi-Specific Designer Proteins for Tumor Therapeutics
Dr Karyn T. O'NEIL
ARō BIOTHERAPEUTICS, Philadelphia, United States
Coffee Break
Exhibitor Short Presentation: WuXi AppTec
Crelux – A Fully Integrated Offering, from Protein to Screen, Through Crystallography Confirmation and Beyond.
Dr Thomas WALDMANN
CRELUX, A WUXI APPTEC COMPANY, Martinsried, Germany
IL13 - Emerging Higher Order Structure Techniques in Biotherapeutics Development
Dr Tapan K. DAS
BRISTOL-MYERS SQUIBB, New York, United States
Poster Prizes and Closing Remarks
Farewell Lunch & Networking
End of the Conference